Synartro

Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

Fredrik Lehmann

Founder and Chairman

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.